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Abstract 
Background: Dementia is the fifth leading cause of death worldwide with significant effects on healthcare 
costs and caregiver demands. Therapy up to this point has only shown marginal benefit in delaying the 
disease. Focus on preventative treatment now is of upmost importance. The link between herpes virus 
infection and the development of dementia has been well researched, and is an area of focus that may 
result in preventative therapy. The aim of this study is to assess the efficacy of herpes antiviral treatment 
in the prevention of dementia. 
Methods: An exhaustive search of medical literature, including the databases Medline: Pubmed, 
ClinicalKey, Web of Science and CINAHL, was completed using the following search terms: alzheimer OR 
alzheimer's OR dementia AND herpes AND risk AND antiviral OR anti- herpetic. Studies were assessed for 
quality using GRADE criteria. 
Results: A total of 14 articles were screened, 2 of which met inclusion criteria. Both were population-
based retrospective cohort studies based in Taiwan. Both studies found a significant association 
between antiviral therapy for HSV and HZV infections and decreased risk of dementia. Due to the 
limitations of the current studies further research is required which address a broader population and 
utilize more sensitive study protocols such as a randomized controlled trial. 
Conclusion: Antiviral therapy is associated with a significant decrease in the development of dementia. 
Further research is warranted to assess the link between these findings. 
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Abstract   
Background: Dementia is the fifth leading cause of death worldwide 
with significant effects on healthcare costs and caregiver demands. 
Therapy up to this point has only shown marginal benefit in delaying 
the disease. Focus on preventative treatment now is of upmost 
importance. The link between herpes virus infection and the 
development of dementia has been well researched, and is an area of 
focus that may result in preventative therapy. The aim of this study is 
to assess the efficacy of herpes antiviral treatment in the prevention of 
dementia.   
Methods:  An exhaustive search of medical literature, including the 
databases Medline: Pubmed, ClinicalKey, Web of Science and CINAHL, 
was completed using the following search terms: alzheimer OR 
alzheimer's OR dementia AND herpes AND risk AND antiviral OR anti-
herpetic. Studies were assessed for quality using GRADE criteria.  
Results: A total of 14 articles were screened, 2 of which met inclusion 
criteria. Both were population-based retrospective cohort studies 
based in Taiwan. Both studies found a significant association between 
antiviral therapy for HSV and HZV infections and decreased risk of 
dementia. Due to the limitations of the current studies further research 
is required which address a broader population and utilize more 
sensitive study protocols such as a randomized controlled trial.    
Conclusion: Antiviral therapy is associated with a significant decrease 
in the development of dementia. Further research is warranted to 
assess the link between these findings.  
Keywords: Alzheimer dementia, Herpes virus, HSV, HCV, antiviral 
therapy 
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Decreasing the Incidence of Dementia through 
Treatment of Herpes Virus with Antiviral Therapy 
BACKGROUND 
 Herpes zoster and simplex-1 viruses are among the most 
prevalent infections in the human population. Herpes simplex-1 
(HSV1) is found in ∼90% of population worldwide.1 Varicella zoster 
virus (VZV), or chickenpox, is the primary infection that leads to the 
latent infection of herpes zoster (HZ) and can be found in over 95% of 
the human population over 50 years old.2 For this reason there is a 
higher risk for this population in developing HZ. The hypothesis behind 
the link between herpes virus and dementia has been purported for 
several decades, with Ball3 establishing a link between acute herpes 
encephalitis and Alzheimer’s disease (AD) within the limbic system, an 
area vital for the utilization of memory recall. The pathological 
mechanism that was proposed is that fibers from the trigeminal 
ganglia innervate different vessels and meninges within the region of 
the limbic system.3 Latent reactivation of herpes virus, which lays 
dormant in the trigeminal nerve, may cause an increased risk of 
developing dementia. More recent research discovered that HSV1 was 
detected within and may cause the induction of beta-amyloid 
plaques4’5 as well as tau-proteins in human brain tissue, both 
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pathological markers of AD.6’7 Further research is necessary to 
determine the exact mechanism of these findings; however, the 
aforementioned evidence warrants exploration of the link between 
herpes and dementia. 
 AD is the most common form of dementia, and it affects over 20 
million people worldwide. It is predicted that the prevalence of AD will 
rise with the growth of the elderly population. It is currently the sixth 
leading cause of death in the United States.8’9 In 2015, healthcare 
costs associated with dementia in long-term care facilities and hospice 
care totaled $226 billion.9 With the increase in incidence and cost of 
dementia, it is essential that we continue to pursue therapeutic options 
to delay or diminish its development.  
 Treatment for AD focuses on the management of symptoms and 
delaying the progression of the disease. Beneficial outcomes, however, 
are not consistent. Many of the therapeutic agents that exist today to 
delay the progression of AD, such as memantine, show marginal 
improvement in cognitive assessment of patients with dementia.10 
Non-pharmacological treatment focuses on cognitive rehabilitation 
through exercise and cognitive stimulation and has shown to improve 
cognitive function in those diagnosed with AD.11 Although these 
treatments do mildly improve cognition, their results are temporary 
 - !  - Revised 23Jul20188
and reveal the need for a more intense focus on the prevention of 
dementia. With consistent data showing a strong correlation between 
herpes virus infection and the development of dementia, new research 
is investigating the possibility of antiviral therapy as an effective 
preventative treatment for incident dementia.12,13 
 The focus of this systematic review will be on studies that show 
an association between treatment of herpes virus with antiviral 
treatment and subsequent decreased dementia. These studies give 
evidence to tailor and develop preventative treatment in those infected 
with herpes, which can benefit by way of healthcare savings and 
reduced burden on caregivers as well as the potential for vaccine 
development in infancy to prevent herpes. Our aim is to determine the 
feasibility of these claims and where to direct further research. 
METHODS 
An exhaustive search of Medline: Pubmed, ClinicalKey, Web of Science 
and the Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) was completed using the following search terms: alzheimer 
OR alzheimer's OR dementia AND herpes AND risk AND antiviral OR 
anti-herpetic. Eligibility criteria were broad and required publications to 
be written in English and include the outcome of antiviral therapy on 
risk of developing dementia. Animal based studies were excluded. 
Studies were assessed using GRADE criteria.  
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RESULTS 
A total of 14 articles were reviewed. After screening the abstracts of 
the available literature there were 2 studies12,13 that met inclusion 
criteria. The 2 articles12,13 were population-based retrospective cohort 
studies. See Table 1. A third controlled laboratory study using animal 
cell cultures was identified but excluded from analysis due to the 
limitations of applicability to clinical practice.14    
Chen et al   
 The authors of this study12 used a population-based 
retrospective cohort model to investigate the association between 
herpes zoster and dementia as well as the role of antiviral therapies in 
treating herpes zoster and subsequent incident dementia. The selected 
cases were identified using the ICD-9 CM codes from the National 
Health Insurance Research Database (NHIRD) in Taiwan. A total of 
39205 subjects with herpes zoster were identified and 39205 case 
control subjects were randomly sampled from the database matching 
for age, sex, residence and index date, which was the date of herpes 
zoster diagnosis. Case and control subjects were followed for incidence 
of any type of dementia including but not limited to senile, vascular, 
and Alzheimer disease.12    
 Dementia was defined as 1 inpatient diagnosis or 3 or more 
outpatient diagnoses. All subjects diagnosed before the index date 
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were excluded from analysis. The exposure group was defined by use 
of antiviral therapy for herpes zoster including all formulations of 
acyclovir, tromantadine, famciclovir, and valacyclovir. The data for drug 
prescriptions was extracted from the NHIRD and the medication had to 
be started after the index date for inclusion in the analysis.12    
 The statistical analysis was done using a Cox regression analysis 
with competing risk model which adjusted for identified covariate risk 
factors such as alcohol use disorder, depression and residence. 
Statistical analysis revealed that of the total subjects 4204 were 
diagnosed with dementia and 2174 of those were in the herpes zoster 
cohort. After adjusting for confounding factors such as depression, 
autoimmune disease and alcohol use disorder there was a statistically 
significant increased association of dementia for the herpes zoster 
cohort (adjusted HR: 1.11; 95% CI, 1.04–1.17). In addition, antiviral 
therapy was found to significantly reduce the risk of developing 
dementia with an adjusted HR of 0.55 (95% CI, 0.40–0.77).12        
Tzeng et al  
 The goal of this study13 was to investigate the relationship 
between HSV infection and dementia as well as the role of antiviral 
therapy in treating HSV infections and incident dementia. The design of 
the study was a population-based matched cohort where authors 
identified participants from the NHIRD and Longitudinal Health 
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Insurance Database (LHID), 2 widely encompassing health insurance 
databases in Taiwan. Subjects with an HSV infection were identified 
using the ICD-9-CM codes, a previously validated means of diagnostic 
identification. A total of 8362 subjects were selected with the inclusion 
criteria of age over 50 and newly diagnosed HSV infection, which was 
marked as the index date. Each case subject was frequency matched 
for sex, age and index date with 3 case control subjects from the 
NHIRD.13  
 The authors accounted for multiple covariates including age, sex, 
residence, income and Charlson Comorbidity Index (CCI). The CCI 
includes 3 common risk factors for the development of AD, which are 
diabetes, cerebrovascular disease and stroke. Antiviral therapy was 
defined by use of acyclovir, famciclovir, ganciclovir, idoxuridine, 
penciclovir, tromantadine, valaciclovir or valganciclovir.13  
 Participants were followed for a 10-year period until onset of 
dementia, which was defined as Alzheimers, vascular or other 
dementia. Statistical analysis was done using the Fisher exact to 
determine cohort differences, after adjusting for covariates a 
multivariate Cox proportional hazards regression showed that subjects 
with genital or non-genital HSV infections were at a statistically higher 
risk of developing any type of previously defined dementia. A total of 
7215 participants on antiviral therapy were compared to a subgroup of 
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1147 participants not on antiviral therapy. Patients on any type of 
antiviral treatment were associated with a decreased risk of overall 
dementia (adjusted HR 0.092, 0.079-0.108, P < 0.001). Investigators 
did note the differences between the populations of treatment 
subgroups. Those on antivirals tended to live in higher urban areas in 
Northern Taiwan and were associated with greater CCI scores.13       
DISCUSSION 
 Dementia remains one of the leading causes of death worldwide, 
with burden on caregivers and the healthcare system being a major 
driving force to discovering therapeutic options to delay or prevent the 
disease. Therapeutic interventions thus far have been limited to 
supplements, medications, and cognitive therapy, which have only 
shown marginal improvement in delaying the progression of the 
disease. It is therefore imperative to seek out and discover 
preventative options that can relieve patients, families, and caregivers 
from this devastating disease. A link between herpes virus and 
dementia has been well established and continues to be an area of 
focus in the prevention of dementia. With the prevalence of herpes 
virus affecting over 90 percent of the population, there is potential to 
reach a practice changing preventative intervention. This analysis aims 
to determine the efficacy of antiviral treatment as a potential 
preventative option and where to direct further research.  
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 This extensive systematic review found 2 articles12,13 which 
showed an association between decreased risk of dementia and 
treatment of HSV or HZV infections with antiviral therapy. Both articles 
were population-based cohort studies, which extracted data from the 
NHIRD in Taiwan. The major difference between the 2 articles was the 
case subject variable, HSV13 versus HZV12 infections. The NHIRD is one 
of the world’s largest health insurance databases and accounts for over 
99% of Taiwan’s population. For that reason it is a very comprehensive 
database for research purposes but applicability to a larger population 
remains questionable. Although both studies12,13 were able to show a 
statistically significant link between antiviral therapy and decreased 
risk of dementia, the participant population is specific to Taiwanese 
residents, which increases the possibility of confounding variables such 
as diet, genetics or even climate.  
 A GRADE analysis rated both articles as moderate quality 
because although both studies revealed a large magnitude of effect of 
antiviral therapy, their nature as observational studies implies inherent 
limitations for that effect. Another limitation to these studies is the 
unclear mechanism by which herpes is related to the development of 
dementia. Although research has shown beta-amyloid plaques and tau 
proteins with herpes DNA in brain tissue, there remains the fact that 
other infectious diseases, such as Helicobacter pylori, may contribute 
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to the development of dementia.15 Further research must be 
established discovering the mechanism behind herpes infection and 
dementia; however, our analysis reveals a large effect between 
treating herpes and preventing dementia, thus suggesting a link. 
 Despite the limitations of these studies, further research is 
required as both12,13 have shown a significant correlation for 
decreasing the incidence of overall dementia. This association has also 
been shown in a laboratory study14 which found that the use of 
antiviral agents, acyclovir and pencyclovir, decreased the accumulation 
of Aβ and P-tau, proteins associated with AD, in cell cultures acutely 
infected with HSV1.  
  The overall results of this review indicate the need for further 
research. Prospective cohort studies utilizing antiviral therapy and 
placebo controls are warranted based on the results of current 
research. Future studies should be conducted outside of Taiwan to 
decrease the likelihood of confounding variables contributing to the 
aforementioned results. Although these studies do not provide 
conclusive evidence for the use of anti-herpetic therapy in the direct 
prevention of incident dementia, there is no reason to avoid treating 
latent herpes outbreaks with antivirals as any potential risks are low.  
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CONCLUSION 
 Dementia is a leading cause of death worldwide with no effective 
treatment options available. A number of diseases and co-morbid 
conditions have been linked to the development of dementia, most 
recently HSV1 and HZV infections. This review investigated the efficacy 
of treating patients with herpes virus outbreaks with antiviral therapy 
as a means of decreasing the likelihood of developing dementia later in 
life. Two studies were found which both uncovered a significant 
association between herpes-targeted antiviral therapy and decreased 
risk of developing dementia. Further research is warranted in the form 
of prospective cohort studies and randomized controlled trials utilizing 
antiviral therapy and placebo controls. Continued research could 
solidify this important discovery in preventative treatment of dementia 
for patients with HSV1 or HZV. 
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Table 1: Quality Assessment of Reviewed Articles
Study Design
Downgrade Criteria Upgrade Criteria
Qualit
y
Limitatio
ns
Indirect
ness
Inconsist
ency
Impreci
sion
Publicat
ion bias
Chen et 
al1
Coh
ort
Not 
Seriousa
Not 
Serious
Not 
Serious
Not 
Serious
Unlikely Large 
Magnitude of 
Effecta
Moder
ate
Tzeng 
et al2
Coh
ort
Not 
Serious
Not 
Seriousb
Not 
Serious
Not 
Serious
Unlikely None Low
a RR decreased for patients on anti-herpetic medication 
bPatient population is specific to Taiwan so may have unseen confounding variables 
cPrescriptions of antiviral therapy were associated with a reduced risk of developing 
dementia following the diagnosis of herpes zoster (HR =0.55; 95% CI, 0.40–0.77).   
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